作者： 翠盖调味研发团队
出版：广东独特风味有限公司
最后更新： 九月 18，2026
WhatsApp与Telegram： +86 189 2926 7983
电子邮件：info@cuiguai.com
An FDA warning letter is a formal written notice from the U.S. Food and Drug Administration to a firm that documents violations of the Federal Food, Drug, and Cosmetic Act (FD&C Act) and its implementing regulations. It is the agency’s principal enforcement instrument short of litigation: a warning letter puts a company on official notice, demands a written corrective response, and becomes a permanent public record in the FDA Warning Letters database. For e-liquid brand owners and flavor concentrate buyers, the practical significance is immediate — a supplier with a citation history can trigger import detentions, destabilize your own compliance files, and complicate a premarket tobacco product application (PMTA) or substantial-equivalence strategy.
The Center for Tobacco Products (CTP) issues the flavor-relevant warning letters that matter most to e-liquid manufacturers, but the flavor industry also sits inside the FDA’s food program. A single concentrate can serve a beverage line, a bakery application, and an e-liquid base at the same time, which means a flavor house can face citations under tobacco rules, food-additive rules, and labeling rules administered by different FDA centers. This article walks through the citation categories that actually appear in FDA warning letters, the verified regulatory facts behind each category, and the documentation you should demand from any flavor concentrate supplier that feeds a U.S. product line.
If your brand is pursuing premarket authorization, the quality of the supplier’s flavor documentation is decisive. Our PMTA flavor master files support program explains how Full Ingredient Disclosure, batch GC-MS data, thermal stability analysis, and toxicological summaries are assembled for FDA review — the same documentation baseline that keeps a formulation out of the citation patterns described below.
FDA Warning Letters: Common Flavor-Related Citations for E-Liquid Brands
Warning letters usually begin with a facility inspection, an import examination, or a desk review of a company’s own website, labeling, and advertising. During a facility inspection, FDA investigators record observations on a Form FDA 483, which the firm has an opportunity to address before the agency decides whether a warning letter is warranted. When FDA concludes that violations exist, it issues a letter signed by the issuing office — in the tobacco space, typically the Office of Compliance and Enforcement at the Center for Tobacco Products — and posts it publicly in the FDA Warning Letters database, where it remains searchable by company name, product type, and issue date.
The database is free and public, and it is the first due-diligence screen any buyer should run on a flavor supplier. Search the supplier’s legal name, its trade names, and the names of affiliated brands. A clean record is not a certification of compliance, but a citation history — particularly repeated citations across years — is a documented pattern of regulatory risk that will eventually reach your products.
FDA warning letters routinely require a written response within 15 working days of receipt, describing corrective actions, the dates on which violative products were discontinued, and a plan for maintaining compliance. In FDA’s August 8, 2019 action against four companies selling 44 flavored e-liquid and hookah tobacco products, the agency explicitly requested responses within 15 working days, including discontinuation dates and future-compliance plans. Failure to respond adequately escalates enforcement to civil money penalty complaints, product seizure, or injunction, and adulterated or misbranded products offered for import may be detained or refused admission at the border.
Two structural facts make the program unusually visible. First, warning letters are permanent public documents, so they ripple through distributor due diligence, insurance underwriting, and platform listings for years. Second, FDA does not need to wait for an inspection: a significant share of citations originate from the agency reviewing marketing websites, which is why the language on your product pages and social channels is regulatory evidence.
The most common flavor-related citation in the e-liquid industry is not about the flavor chemistry at all — it is about the absence of marketing authorization for the flavored product. Under the Tobacco Control Act of 2009, any tobacco product that was not commercially marketed in the United States as of February 15, 2007 is a new tobacco product requiring a marketing authorization order under 21 U.S.C. § 387j(c)(1)(A)(i), unless it qualifies for a substantial-equivalence exemption under § 387e(j). E-liquids and their components became subject to FDA jurisdiction through the deeming rule in 21 CFR Part 1100, finalized in 2016, and FDA treats products introduced or modified after the rule’s effective date as unauthorized unless they hold the required authorization.
A new tobacco product without authorization is adulterated under section 902(6)(A) of the FD&C Act (21 U.S.C. § 387b(6)(A)) and misbranded under section 903(a)(6) (21 U.S.C. § 387c(a)(6)), and the acts of selling or holding such a product for sale after interstate shipment are prohibited acts under section 301(k) and 301(p). These statutory citations appear verbatim in FDA’s e-liquid warning letters, which is why regulatory counsel reads them as a checklist: marketing authorization status, substantial-equivalence report status, and documentation of the product’s predicate lineage.
A concrete, verifiable example is the warning letter FDA issued to Vixen Vapors LLC d/b/a Vixen Vapors Pantego on February 15, 2024 (Reference ER2401014), delivered by UPS and electronic mail. FDA’s Center for Tobacco Products determined that the firm manufactured and distributed e-liquid for commercial distribution in the United States without a marketing authorization order, naming the product Vixen Vapors Pompeii 14mg 120ml in the letter. FDA explained that the product is adulterated under 21 U.S.C. § 387b(6)(A) and misbranded under 21 U.S.C. § 387c(a)(6), and reminded the firm that the Consolidated Appropriations Act, 2022 (Public Law 117-103, Division P, Title I, Subtitle B), signed March 15, 2022, extended FDA jurisdiction to products containing nicotine from any source — including synthetic nicotine that is not derived from tobacco.
The letter closed with the standard 15-working-day response demand and a warning that continued violations could lead to civil money penalties, seizure, or injunction, and that violative import shipments may be detained or refused admission. For buyers, the lesson is concrete: every flavored SKU in your portfolio must trace back to a defensible marketing-authorization position, and the flavor concentrate documentation you hold is part of that position.
If you buy concentrates from a flavor house and formulate the finished e-liquid yourself, you inherit the regulatory burden for the finished product. Even a single fruit-flavor line such as our cherry-flavor concentrate range must be backed by complete compound-level documentation, because FDA evaluates the finished product’s components — flavor compounds, carriers, and additives — when it reviews a PMTA or inspects your facility. A supplier that cannot produce ingredient data on request is a compliance liability, not a cost saving.
Flavor Documentation That Survives FDA Inspection: GC-MS, FIDO, and COA
FDA’s guidance document Enforcement Priorities for Electronic Nicotine Delivery System (ENDS) and Other Deemed Products on the Market Without Premarket Authorization (April 2020; Docket FDA-2019-D-0661) tells companies exactly where enforcement will concentrate. The agency announced that it intends to prioritize enforcement for lack of marketing authorization against any flavored, cartridge-based ENDS product other than a tobacco- or menthol-flavored product; against ENDS products that are targeted to minors, whether directly or through media; and against ENDS products whose labeling or advertising causes them to be marketed as modified-risk tobacco products without an FDA order. Flavor is therefore not a side issue — the flavor profile is the defining characteristic that places a product in the priority enforcement tier.
The guidance’s three priority categories map directly onto the flavor supply chain. A fruit-, candy-, or dessert-flavored cartridge product sits in tier one; a product whose packaging or marketing resembles kid-friendly food or beverage items sits in tier two; and any marketing language implying reduced harm without an FDA modified-risk order sits in tier three. Every one of these categories can implicate the flavor concentrate: its identity (tier one), the label and marketing assets built around it (tier two), and the claims made about it (tier three).
Published research confirms the scale and shape of the program. Schillo and colleagues, analyzing FDA warning letters sent to e-cigarette companies between January 1, 2020 and September 9, 2021 (Tobacco Control, 2024; PMID 36229228), coded 303 warning letters: 126 from 2020 and 177 from 2021. The study found that 97.4 percent of the letters went to small online retailers, 94.1 percent of the cited companies were located in the United States, 75.2 percent of the infractions were identified by reviewing a company’s website, and 70.5 percent were PMTA violations. The letters cited 880 products, of which 92.2 percent were e-liquid, with 32.4 percent fruit-flavored and 31.1 percent concept-flavored.
Two practical conclusions follow for flavor buyers. First, flavored e-liquid is the enforcement epicenter, which makes flavor documentation the single most requested category of evidence in the program. Second, the 2020–2021 enforcement wave concentrated on small online retailers; as that layer consolidates, importers, distributors, and manufacturers are squarely in FDA’s field of view, and warning letters naming e-liquid products by name — like the Vixen Vapors letter — show how the agency tracks products through the supply chain.
The best defense against a flavored-product citation is a documented, defensible formulation trail from concentrate supplier to finished SKU. That trail includes additive compliance data across jurisdictions; our GB 41700-2022 additive compliance guide explains how China’s national standard for e-liquid restricts the permitted additive list, a useful cross-check when the same concentrate family is dual-sourced into U.S. and Asian markets. In the U.S. system, the package of Full Ingredient Disclosure, GC-MS batch analysis, Certificates of Analysis, and Safety Data Sheets is what regulatory counsel will assemble to demonstrate good-faith diligence if FDA ever requests information or issues a letter.
21 CFR Part 117 cGMP Compliance for Flavor Concentrate Manufacturing
Flavor concentrate houses that sell into food and beverage applications face a distinct citation family under the FDA food program. Under 21 U.S.C. § 342(a)(2)(C), a food is adulterated if it bears or contains a food additive that is unsafe within the meaning of section 348 — that is, a substance that is not generally recognized as safe (GRAS) among qualified experts and is not the subject of an applicable food additive regulation, food-contact notification, or prior sanction. When a flavor ingredient or carrier is used outside its approved condition of use, FDA may cite the concentrate manufacturer and, in the finished-product context, the formulator who incorporated it.
The flavor industry’s own GRAS system — the Flavor and Extract Manufacturers Association (FEMA) GRAS program — provides the expert-review pathway that most flavor compounds rely on, but GRAS status is substance- and use-specific. A compound that is GRAS for food use is not automatically acceptable as an e-liquid ingredient, and FDA’s PMTA review treats inhalation exposure separately from ingestion. Buyers should therefore ask for each ingredient’s GRAS status, its regulatory listing under 21 CFR Parts 182, 184, and 186 where applicable, and the use-level range the supplier actually validated.
Misbranding citations under 21 U.S.C. § 343 are the second food-side family. A label is false or misleading under § 343(a) if it makes unsubstantiated claims, and § 343(w) requires food labels to declare major food allergens — milk, eggs, fish, crustacean shellfish, tree nuts, peanuts, wheat, and soybeans — with sesame added effective January 1, 2023 under the FASTER Act. Flavor concentrates containing allergen-derived ingredients, such as dairy- or nut-based extracts, drive finished-product allergen declarations, and the supplier’s allergen matrix is the evidence that keeps your labels compliant.
In the tobacco space the misbranding analogue is just as sharp. Finished e-liquid labels must carry the required nicotine warning statement, and any labeling or advertising that implies FDA approval or registration without an order is a serious misbranding issue. FDA has repeatedly acted against firms whose packaging or marketing positioned products as FDA-approved, and the agency’s enforcement-priority guidance treats modified-risk language as a priority category in its own right. Marketing copy is regulatory evidence — review it with the same discipline as the label itself.
The third food-side family is current Good Manufacturing Practice (cGMP) and preventive controls under 21 CFR Part 117, the FSMA-era framework that replaced the older 21 CFR Part 110 rules. Flavor facilities must maintain cGMPs covering sanitation, water safety, allergen cross-contact controls, and employee hygiene; where applicable they must implement a written food safety plan with hazard analysis and risk-based preventive controls; and most facilities must register with FDA under 21 CFR Part 1, Subpart H, with renewed registrations every two years. When an inspection finds failed sanitation, contaminated product, or absent controls, FDA cites specific 21 CFR 117 sections in a warning letter.
For an e-liquid brand, the same GMP discipline governs the quality of the liquid you bottle: concentrate purity, microbial limits, cross-contact prevention, and clean production environments all feed the finished product’s safety profile. Supplier audits should verify that the plant operates under a documented quality system — ISO 22000, HACCP, or equivalent — and that batch records tie every Certificate of Analysis to a specific production run.
A compliance-ready flavor supplier should hand over, on request, the complete documentation set: compound-level Full Ingredient Disclosure with CAS numbers and concentrations; batch GC-MS chromatograms proving formula consistency; a Certificate of Analysis for every lot; Safety Data Sheets; an allergen matrix; and a statement of FEMA GRAS or 21 CFR status for each ingredient. When you receive a fruit concentrate such as our blueberry-flavor concentrate line with this documentation bundle, you have converted a commodity purchase into an audit-ready regulatory asset. When a supplier cannot produce these documents, treat that as the first warning signal you will ever receive — it is far cheaper than the FDA one.
Misbranding Risks in Flavor Labeling: Allergens and Marketing Claims
Need a technical consultation on FDA-facing flavor documentation for your e-liquid line? Our R&D and compliance team can walk you through Full Ingredient Disclosure, GC-MS batch data, Certificates of Analysis, and PMTA support packages tailored to your SKU portfolio — and we will prepare free flavor concentrate samples for your formulation trials.
📞 电话： +86 0769 8838 0789
🌐 网站： https://www.cuiguai.com
📧 电子邮件： info@cuiguai.com
💬 WhatsApp 和电报： +86 189 2926 7983
5. 21 U.S.C. § 387j — Application for Review of Certain Tobacco Products (Cornell Law School Legal Information Institute). https://www.law.cornell.edu/uscode/text/21/387j
